** Pfizer PFE.N said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, as the drugmaker expects to be an "earnings growth" story over the next three years
** Median PT of brokerages covering the stock is $28 - data compiled by LSEG
ENCOURAGING COMMENTARY
** BMO Capital Markets ("outperform", PT: "$30") says outperformance this quarter (particularly on the cost side) positions Pfizer well for the rest of the year, derisking the company's forecast amid a tumultuous economic backdrop
** Jefferies (PT:$32) says PFE reported an ok Q1, adding the company's oncology drugs will start to resonate with investors
** Leerink Partners ("market perform") says the company had encouraging comments on tariffs, dividend and M&A
** J.P.Morgan (PT:$30) believes stronger new launch performance and/or further progress on the drugs in development will be necessary to significantly change the current narrative on the stock, which the brokerage sees as more likely from 2026
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.